News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Depomed, Inc. Announces Completion Of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned
August 15, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Phase I clinical trial to evaluate the delivery and absorption of a compound currently used to treat gastroesophageal reflux disease (GERD).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
MORE ON THIS TOPIC
Alzheimer’s disease
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
April 30, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act
April 30, 2026
·
2 min read
·
Annalee Armstrong
Insights
What makes life science angel investment work?
April 30, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Earnings
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
April 29, 2026
·
3 min read
·
Gabrielle Masson
